Authors: Satoshi Nishiwaki Seitaro Terakura Takahiko Yasuda Nobuhiko Imahashi Hiroshi Sao Hiroatsu Iida Yoshikazu Kamiya Keiko Niimi Yoshihisa Morishita Akio Kohno Toshiya Yokozawa Haruhiko Ohashi Masashi Sawa Yoshihisa Kodera Koichi Miyamura
Publish Date: 2010/02/10
Volume: 91, Issue: 3, Pages: 419-425
Abstract
The indication of allogeneic stem cell transplantation alloSCT for Philadelphia chromosomenegative acute lymphocytic leukemia Ph− ALL from unrelated donors is not established To assess its potency of unrelated patients in first completeremission CR1 transplanted from unrelated donors and the potential prognostic factors affecting the probability of survival we retrospectively analyzed a total of 41 adult Ph− ALL patients in CR1 who underwent unrelated bone marrow transplantation at 6 transplantation centers of the Nagoya Blood and Marrow Transplantation Group between 1993 and 2006 The median age of the 41 patients was 28 years range 18–51 years HLA was matched in 33 transplants with mismatches in 8 HLAA allele mismatch1 HLADR serological mismatch 2 HLADRB1 mismatch 5 Leukemiafree survival LFS at 3 and 6 years from alloSCT was 603 and 477 respectively LFS at 5 years was 621 for those transplanted from HLAmatched donors LFS was significantly lower with HLAmismatched donors due to higher transplantationrelated mortality Relapse was observed in 3 patients Our study suggested that unrelated alloSCT could improve LFS of patients with a potential graftversusleukemia effect Unrelated alloSCT for Ph− ALL patients in CR1 could be more beneficial by reducing TRM such as selecting a HLAmatched donor
Keywords: